Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Phase II Study of Weekly Oxaliplatin and High-dose Infusional 5-Fluorouracil plus Leucovorin in Pretreated Patients with Metastatic Colorectal Cancer

S. CHIARA, M.T. NOBILE, A. GOZZA, P. TAVEGGIA, A. HEOUAINE, I. PASTRONE, P.L. PERCIVALE, R. LIONETTO, O. SANGUINETI and R. ROSSO
Anticancer Research January 2004, 24 (1) 355-360;
S. CHIARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.T. NOBILE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. GOZZA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. TAVEGGIA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. HEOUAINE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. PASTRONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.L. PERCIVALE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. LIONETTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. SANGUINETI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. ROSSO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Chemotherapy with oxaliplatin, fluorouracil (5-FU) and leucovorin (LV) has proven efficacy in patients with advanced colorectal carcinoma (CRC), although the optimal dosage and administration schedule are still unclear. This phase II trial investigated the tolerability and activity of weekly oxaliplatin, high-dose infusional 5-FU and LV in pretreated patients with metastatic CRC. Materials and Methods: Patients received weekly courses of i.v. oxaliplatin 50 mg/m2 (1-h infusion), LV 100 mg/m2 (1-h infusion) and 5-FU 2100 mg/m2 (24-h infusion) until disease progression or unacceptable toxicity. NCI-CTC criteria were used for assessment of side-effects (at each cycle) and WHO criteria for assessment of tumour response (every 8 cycles). For descriptive purposes, time to progression, overall survival and duration of objective response were also calculated. Results: Forty-four patients were enrolled and received a total of 606 cycles (median 13/patient, range 4-33), and 70% of courses (421/606) were delivered at 100% of the planned dose. The most frequent side-effects were gastrointestinal and neurological and incidence rates were: diarrhoea 66% (grade III: 29%), nausea/vomiting 54%, neurotoxicity 34% (grade III: 2%), fatigue 27%, mucositis 22%, leucopenia 14%. No grade IV toxicity was observed. Objective response rates were: partial response 23% (10 patients), stable disease 59% (26) and progressive disease 11% (5). Median time to progression was 7 months, overall survival 13 months and the duration of partial response and stable disease were 9 and 6 months, respectively. Conclusion: The study demonstrated that this regimen has a favourable tolerability profile and is an active combination in the pretreated metastatic CRC patient, deserving further evaluation in phase III trials.

Footnotes

  • ↵* Deceased

  • Received October 22, 2003.
  • Accepted December 22, 2003.
  • Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 24 (1)
Anticancer Research
Vol. 24, Issue 1
January-February 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase II Study of Weekly Oxaliplatin and High-dose Infusional 5-Fluorouracil plus Leucovorin in Pretreated Patients with Metastatic Colorectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Phase II Study of Weekly Oxaliplatin and High-dose Infusional 5-Fluorouracil plus Leucovorin in Pretreated Patients with Metastatic Colorectal Cancer
S. CHIARA, M.T. NOBILE, A. GOZZA, P. TAVEGGIA, A. HEOUAINE, I. PASTRONE, P.L. PERCIVALE, R. LIONETTO, O. SANGUINETI, R. ROSSO
Anticancer Research Jan 2004, 24 (1) 355-360;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Phase II Study of Weekly Oxaliplatin and High-dose Infusional 5-Fluorouracil plus Leucovorin in Pretreated Patients with Metastatic Colorectal Cancer
S. CHIARA, M.T. NOBILE, A. GOZZA, P. TAVEGGIA, A. HEOUAINE, I. PASTRONE, P.L. PERCIVALE, R. LIONETTO, O. SANGUINETI, R. ROSSO
Anticancer Research Jan 2004, 24 (1) 355-360;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Hepatic Arterial Infusion with Oxaliplatin, Irinotecan and Doxifluridine for Unresectable Liver Metastases of Colorectal Cancer
  • In Reply
  • Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901
  • Google Scholar

More in this TOC Section

  • Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer
  • Pathologic Complete Response (pCR) in Patient With Myxofibrosarcoma Who Underwent Neoadjuvant Radiation Concurrent to Complementary and Alternative Medicine
  • Machine Learning Model to Guide Empirical Antimicrobial Therapy in Febrile Neutropenic Patients With Hematologic Malignancies
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire